Overview

Buprenorphine for Cancer Pain

Status:
Recruiting
Trial end date:
2024-10-10
Target enrollment:
Participant gender:
Summary
This study will evaluate patients on both buprenorphine and full agonist opioids (FAO) to assess for withdrawal symptoms. Patients will be evaluated by clinicians and using validated tools to assess for pain and withdrawal. At the same time, patients will use a CPM Rx application on their phone to track medication use.
Phase:
Phase 4
Details
Lead Sponsor:
Fox Chase Cancer Center
Treatments:
Buprenorphine